FNWFX
Price
$106.02
Change
-$1.96 (-1.82%)
Updated
Jul 2 closing price
Net Assets
90.88B
FTMKX
Price
$51.84
Change
-$0.49 (-0.94%)
Updated
Jul 2 closing price
Net Assets
13.85B
Interact to see
Advertisement

FNWFX vs FTMKX

FNWFX vs FTMKX Comparison Chart in %
View a ticker or compare two or three
VS
FNWFX vs. FTMKX commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FNWFX is a Buy and FTMKX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FNWFX has more cash in the bank: 90.9B vs. FTMKX (13.9B). FNWFX pays higher dividends than FTMKX: FNWFX (1.24) vs FTMKX (0.81). FNWFX was incepted earlier than FTMKX: FNWFX (9 years) vs FTMKX (22 years). FTMKX (1.42) is less costly to investors than FNWFX (0.57). FTMKX is a more actively managed with annual turnover of: 58.00 vs. FNWFX (46.00). FTMKX has a lower initial minimum investment than FNWFX: FTMKX (0) vs FNWFX (1000000). FTMKX annual gain was more profitable for investors over the last year : 48.24 vs. FNWFX (20.57). FTMKX return over 5 years is better than : 41.67 vs. FNWFX (15.20).
FNWFXFTMKXFNWFX / FTMKX
Total Expense Ratio0.571.4240%
Annual Report Gross Expense Ratio0.571.4240%
Fund Existence9 years22 years-
Gain YTD13.71923.72358%
Front LoadN/A4%-
Min. Initial Investment10000000-
Min. Initial Investment IRAN/A500-
Net Assets90.9B13.9B654%
Annual Yield % from dividends1.240.81153%
Returns for 1 year20.5748.2443%
Returns for 3 years48.6391.0553%
Returns for 5 years15.2041.6736%
Returns for 10 yearsN/A155.07-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAGHX29.890.83
+2.86%
Virtus KAR Health Sciences A
MINRX38.350.58
+1.54%
MFS International Intrinsic Equity R1
JORRX20.590.13
+0.64%
Janus Henderson Global Select R
TWAIX14.270.01
+0.07%
Thrivent International Equity S
IMIDX21.97-0.23
-1.04%
Congress Mid Cap Growth Institutional